医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Kraig Biocraft Laboratories COO Travels to Vietnam to Assist Transition of Production Operations to New Factory

2019年10月02日 PM08:05
このエントリーをはてなブックマークに追加


 

ANN ARBOR, Mich.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that Jon Rice, the Company’s chief operating officer, will travel to Vietnam, this week, to work with the Company’s subsidiary, Prodigy Textiles, on the transition of silk production operations into its recently renovated facility in Quang Nam province. During this trip, Rice expects to review the completed facility improvements, coordinate operations with Prodigy Textiles senior staff and production workers, finalize production and transportation logistics, discuss production throughput rates and targets, as well as review the security and quality control systems being implemented.

“Our staff, in the U.S. and Vietnam, has put an incredible amount of effort into establishing and preparing Prodigy Textiles to disrupt the performance textile markets. Our team has pushed through incredible challenges to bring this factory online. We are now ready to put it to work, bringing our recombinant spider silk technology to market. I expect to be able to share more information about my trip and details about our operations with our shareholders early next week,” said Rice.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191002005155/en/

CONTACT

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report